The pharmaceutical industry continues to be a hotbed of patent innovation. Activity is driven by the evolution of treatment paradigms, and the gravity of unmet needs, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence. In the last three years alone, there have been over 787,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Nanomedicine in pharma: mRNA delivery lipid nanoparticles. Buy the report here.

Smarter leaders trust GlobalData

According to GlobalData’s Technology Foresights, which uses over 668,000 patents to analyze innovation intensity for the pharmaceutical industry, there are 80+ innovation areas that will shape the future of the industry.

mRNA delivery lipid nanoparticles is a key innovation area in nanomedicine

The concept of messenger ribonucleic acid (mRNA) delivery lipid nanoparticles involves the use of lipid-based nanoparticles to deliver mRNA to specific cells in the body. These nanoparticles are formulated to protect the mRNA from degradation and facilitate its uptake by target cells, allowing to produce specific proteins or immunological responses.

GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 30+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of mRNA delivery lipid nanoparticles.

Key players in mRNA delivery lipid nanoparticles – a disruptive innovation in the pharmaceutical industry

‘Application diversity’ measures the number of applications identified for each patent. It broadly splits companies into either ‘niche’ or ‘diversified’ innovators.   

‘Geographic reach’ refers to the number of countries each patent is registered in. It reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.  

Patent volumes related to mRNA delivery lipid nanoparticles

Company Total patents (2010 - 2022) Premium intelligence on the world's largest companies
Moderna 336 Unlock Company Profile
Sanofi 215 Unlock Company Profile
Takeda Pharmaceutical 93 Unlock Company Profile
Arbutus Biopharma 51 Unlock Company Profile
Curevac 50 Unlock Company Profile
CRISPR Therapeutics 39 Unlock Company Profile
Alnylam Pharmaceuticals 33 Unlock Company Profile
Provecs Medical 20 Unlock Company Profile
Bayer 18 Unlock Company Profile
BioNTech 16 Unlock Company Profile
Japan Science and Technology Agency 14 Unlock Company Profile
Intellia Therapeutics 13 Unlock Company Profile
Arcturus Therapeutics 10 Unlock Company Profile
Aadigen 7 Unlock Company Profile
Generation Bio 7 Unlock Company Profile
Teloregen 7 Unlock Company Profile
Adhera Therapeutics 7 Unlock Company Profile
Ramot 5 Unlock Company Profile
Avidity Biosciences 5 Unlock Company Profile
Vertex Pharmaceuticals 3 Unlock Company Profile
InnoTherapy 3 Unlock Company Profile
Centro De Investig Y De Estudios Avanzados Del I P N 2 Unlock Company Profile
RoverMed BioSciences 2 Unlock Company Profile
TRON 2 Unlock Company Profile
Eloxx Pharmaceuticals 2 Unlock Company Profile
Toshiba 2 Unlock Company Profile
Dynavax Technologies 2 Unlock Company Profile
AstraZeneca 2 Unlock Company Profile
Shenzhen People's Hospital 2 Unlock Company Profile
Protiva Biotherapeutics 2 Unlock Company Profile
Otsuka 1 Unlock Company Profile
Samsung Group 1 Unlock Company Profile
CureLab Oncology 1 Unlock Company Profile
Novartis 1 Unlock Company Profile
Zhang Yuan 1 Unlock Company Profile
ApicHope Pharmaceutical 1 Unlock Company Profile
Myeloid Therapeutics 1 Unlock Company Profile
Innorna 1 Unlock Company Profile

Source: GlobalData Patent Analytics

Moderna is one of the leading patent filers in mRNA delivery lipid nanoparticles. The biotechnology company focuses on the development of mRNA therapeutics and vaccines. The company develops and discovers drugs that produce proteins or antibodies inside patient cells. Its pipeline includes various drug modalities such as prophylactic vaccines, therapeutic vaccines, intratumoral immuno-oncology candidates, localized therapeutics, and liver intracellular candidates. Moderna, through its mRNA therapeutics that are delivered using a lipid nanoparticle (LNP) technology platform, develops and produces human proteins, antibodies, and novel proteins, which help in preventing, treating, and curing diseases. Sanofi and Takeda Pharmaceutical are some of the other key patent filers in mRNA delivery lipid nanoparticles.

In terms of application diversity, Moderna leads the pack, while Avidity Biosciences and Intellia Therapeutics stood in the second and third positions, respectively. By means of geographic reach, Curevac held the top position, followed by Provecs Medical and Arbutus Biopharma.

To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Nanotechnology in Medicine.

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Patent Analytics tracks patent filings and grants from official offices around the world. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.